| Japanese |
|---|
| Title | 131Iの肝内集積, とくに131Iによる肝シンチグラム描出の可能性 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 立野育郎, 加藤外栄** |
|---|
| Authors(kana) | |
|---|
| Organization | **国立金沢病院特殊放射線科. |
|---|
| Journal | 核医学 |
|---|
| Volume | 5 |
|---|
| Number | 2 |
|---|
| Page | 135-141 |
|---|
| Year/Month | 1968/7 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. はじめに」血中へ移入されたヨードイオンが, 甲状腺のみならず, ほとんどただちに, 胃, 唾液腺などにおいてextrathyroidalに濃縮されることが知られており, われわれは131Iを静脈注射して胃ならびに唾液腺スキャニグングについて研究, 報告した. また, 甲状腺131I摂取率の測定にさいして腎機能が低下していると, extrathyroidalに唾液腺, 胃はもちろん, 腎, 膀胱, および心などの血液プールにも131Iの放射能が長時間にわたりかなりみとめられることを注目し, また, 授乳中では乳汁中に, 発汗多量の場合は汗中へもかなりの131Iが分泌されることを報告した. 今回, われわれは, 甲状腺機能亢進症に対する131I治療にさいして, 肝が131Iを集積して肝をシンチスキャニングによって描出することに成功したので報告する. なお, スキャナーは, 島津製で3"×2"結晶のものを用いた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | |
|---|
| English |
|---|
| Title | 131I Accumulation in Liver, especially on the Possibility of Delineation of Liver by Scintiscanning with 131I |
|---|
| Subtitle | |
|---|
| Authors | I. Tatsuno, S. Kato |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Radiology, National Kanazawa Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 5 |
|---|
| Number | 2 |
|---|
| Page | 135-141 |
|---|
| Year/Month | 1968/7 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] We already reported that stomach, salivary gland and breast can be delineated by scintiscanning with 131I because of the extrathyroidal 131I distribution in the gastric gland, salivary gland and mammary gland. Furthermore, we proved that in the case of renal hypofunction administered 131I was retained for a pretty long time in the blood pool (e. g. heart) and kidney. Recently we have discovered that the liver can be delineated by the scanning in some of hyperthyroidic patients following the administration of therapeutic dose of 131I. The time of maximum radioactivity of 131I on the liver is noticed to be 3 to 5 days after the oral administration ot Na131I. Following this peak time, radioactivity in the liver shows a decrease of 50% within 4 to 6 days, while the liver excretes radioiodine into the bile. Comparing the hyperthyroidic cases in which liver can be scintiscanned with therapeutic 131I dose (Group A) with the hyperthyroidic ones in which liver can not be scintiscanned (Group B), it has been found that resin sponge uptake, basal metabolic rate and alkaline phosphatase are higher in Group A than in Group B, and total cholesterol level in serum is lower in Group A than in Group B, whereas the both groups show no significant difference as to thyroid 131I uptake. These characteristic findings in laboratory tests may suggest the existence of more severe grade of thyrotoxicosis in Group A. Then supposing the probable close relationship between the 131I accumulation in the liver and the thyroid hormone level in blood, we have tried to scintiscan the liver with 131I-labelled 1-thyroxine injected intravenously. The result is that we have succeeded in getting excellent scintigrams in even the cases of Group B. This method has advantages of reducing the radiation dose of liver compared with one using colloidal 198Au and of delineating liver more truthfully compared with one using 131I-rose bengal in which small artificial defects in the pattern of liver and bowel artifacts are disturbing. While we are eagerly investigating the mechanism of 131I accumulation in liver following the administration of 131I therapeutic dose, we may suggest that the liver plays an important role in the regulation of the blood level of the thyroid hormons. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|